
Novo Nordisk Pharma sp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Novo Nordisk Pharma Sp. z o.o. is the Polish entity of the global healthcare company Novo Nordisk, founded in Denmark in 1923. The company develops therapies for people with diabetes and other serious chronic diseases.
Financials
Revenue history (in m)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 47 days late). All were audited by a statutory auditor.
- 202507/07/2026
- 202412/06/2025
- 202326/06/2024
- 202206/06/2023
- 202131/08/2022
- 202001/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Pharmaceutical products
- Injection pens
Websites
The company has 4 websites. The company uses the Meta advertising pixel (Facebook, Instagram).
- novonordisk.plNovo Nordisk Polska
- cardioconnect.plCardioConnect 2025Apache
- gopump.plgopump - GoPump: cukrzycaWordPress 7.1DDiviRRank Math
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 4 marks have expired or were not registered. The first mark was filed in 2001.
| Mark | Protected until | |
|---|---|---|
| i NovoSerwis | – | |
| @ NovoWebCafe | – | |
| @ novowebcafe | – | |
| i novoserwis | – |
Authorized Representatives
Manner of representation
Each member of the management board is authorised to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Novo Nordisk Region Europe A/s | 18,041 | $2,436,655.86 | 99.9945% |
Others | 1 | $135.06 | 0.0055% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the Novo Nordisk A/S (Denmark) group. Its direct owner is Novo Nordisk Region Europe A/S (Denmark). The group has 6 companies, 4 of them abroad.
| Name | Country |
|---|---|
| NNE A/S | |
| Novo Nordisk Finance (Netherlands) B.V. | |
| Novo Nordisk Health Care AG | |
| Novo Nordisk Service Centre (India) Private Limited |
Bank accounts
Registered as a VAT taxpayer on 1996-07-01.
73 1050 0086 1000 0090 3050 2950
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 1.1MPLN 1,088,170 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 3, 2014 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Sanofi sp. z o.o. | $384,123,246.36 | sanofi.com | ||
| Bristol-Myers Squibb Polska sp. z o.o. | $230,722,737.87 | bms.com | ||
| Accord Healthcare Polska sp. z o.o. | $178,502,388.11 | accord-healthcare.pl | ||
| Gilead Sciences Poland sp. z o.o. | $150,844,944.19 | gilead.com | ||
| Reckitt Benckiser (Poland) S.A. | $148,551,741.42 | akcjonariuszerb.pl | ||
| Abbott Medical sp. z o.o. | $146,210,029.73 | abbott.com | ||
| Pfizer Polska sp. z o.o. | $110,632,345.55 | pfizer.pl | ||
| Ipsen Poland sp. z o.o. | $94,814,847.87 | ipsen.com | ||
| Magnapharm Poland sp. z o.o. | $90,512,785.67 | magnapharm.pl | ||
| Vantage Trading sp. z o.o. | $24,835,003.93 | vantages.pl |
Change history
| Date | Event | |
|---|---|---|
| 2018-11-16 | Address change (Ul. Komitetu Obrony Robotników 45b, 02-146, Warszawa → Ul. Krakowiaków 46, 02-255, Warszawa) | |
| 2018-02-07 | Address change (17 Stycznia 45 B, 02-146, Warszawa → Ul. Komitetu Obrony Robotników 45b, 02-146, Warszawa) | |
| 2015-02-13 | Share capital reduction (29,021,000.00 PLN → 9,021,000.00 PLN) | |
| 2008-12-18 | Address change (17 Stycznia 45 B, 01-002, Warszawa → 17 Stycznia 45 B, 02-146, Warszawa) | |
| 2008-12-01 | Address change (Mineralna 15, 02-274, Warszawa → 17 Stycznia 45 B, 01-002, Warszawa) |
FAQ
Last updated: 2026-10-07